Related Experiment Video
Updated: Oct 10, 2025

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Application of the individualized objectives defined by the European 2019 lipid guidelines in patients with type 2
David Martín Enguix1, Abraham Hidalgo Rodríguez2, María Sánchez Cambronero3
1Centro de Salud La Zubia, Distrito Sanitario Granada Metropolitano, La Zubia, Granada, España.
Background And Objective:
Cardiovascular disease is one of the main complications of people with type 2 diabetes (T2D). The ESC/ESA 2019 lipid guide has led to a change in dyslipidemia control. We analyze the evolution of the lipid profile, the fulfillment of the low-density cholesterol (LDL-C) targets, how patients are classified and the impact of this guide on lipid control in T2D patients.
Materials And Methods:
A prospective cohort study from 2017 to 2020 from a cohort of 297 T2D out of a total of 1229 (95% confidence level). We classified patients according to their cardiovascular risk and whether they met or not their LDL-C goal.
Results:
Age 62.58±10.68 years; 52.79% men. Mean LDL-C levels 116.2 at baseline and 100.2mg/dL at 4 years (P<.001). They met their individualized LDL-C target after publication of the guide: 57 (21.67%). There were more controls who were under 65 years (57.9 vs. 36.9%; P<.01; RR 0.83), men (66.7 vs. 49.5%; P<.05; RR 0.86) and smokers (17.5 vs. 7.8%; P<.05). A percentage of 74.23 had a high cardiovascular risk and a target LDL-C<70mg/dL.
Conclusions:
Since the publication of the ESC/ESA 2019 lipid guide, a decrease in LDL-C levels has been observed. Only one in 5 patients fulfill their individualized LDL-C target. Male patients, under 65 years of age and smokers presented an advantage in meeting their goal. Most T2D patients have a high cardiovascular risk, and the predominant LDL-C target is less than 70mg/dL.
More Related Videos
08:44Preparation, Administration, and Assessment of In Vivo Tissue-Specific Cellular Uptake of Fluorescent Dye-Labeled Liposomes
Published on: July 30, 2020
06:16Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies
Published on: July 28, 2023
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Atherosclerosis III: Management
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Dosage Regimen: Individualization
Lipid-Lowering Drugs: Statins and Miscellaneous Agents